Sanofi to buy Kadmon for $1.9bn, expanding transplant-drug portfolio
Drug major Sanofi has agreed to buy US biopharmaceutical company Kadmon Holdings Inc. for $1.9 billion, expanding its transplant-drug portfolio.
Shareholders of Kadmon common stock...